A round of financing has pulled in $14.8 million for ivWatch, which makes the FDA-cleared ivWatch Model 400 device to provide continuous monitoring of peripheral IV for the detection of infiltration and extravasation events. The company intends to use the money for strategic partner activities and direct go-to-market efforts.
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.